Abstract
Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.
Original language | English |
---|---|
Pages (from-to) | 395-398 |
Number of pages | 4 |
Journal | International Congress Series |
Volume | 1252 |
Issue number | C |
DOIs | |
Publication status | Published - Jun 1 2003 |
Externally published | Yes |
Keywords
- Alzheimer's disease
- Amyloid β
- Anti-amyloidogenic properties of melatonin
- Antioxidant properties of melatonin
- Melatonin
ASJC Scopus subject areas
- Medicine(all)